Skip to main content
SpringerLink
Log in

Single Dose Preemptive Plerixafor for Stem Cell Mobilization for ASCT After Lenalidomide Based Therapy in Multiple Myeloma: Impact in Resource Limited Setting

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Peripheral blood stem cell mobilization with cytokines for autologous stem cell transplant in multiple myeloma is adversely affected by initial induction therapy consisting of either Lenalidomide or cytotoxic drugs, with failure rates of up to 45%. The use of Plerixafor with G-CSF for PBSC mobilisation significantly improves the chances of a successful mobilization. Plerixafor is a costly therapy and increases the overall costs of ASCT which can affect the number of patients being taken up for ASCT in resource limited settings. We prospectively studied the impact of single dose preemptive Plerixafor for PBSC mobilization in patients with prior Lenalidomide exposure. 26 patients who had received Lenalidomide based induction protocol underwent PBSC mobilisation during the study period with G-CSF 10 μg/kg/day SC for 4 days and single dose preemptive Plerixafor 240 μg/kg SC stat 11 h before the scheduled PB stem cell harvest on D5, based on a D4 PB CD34+ counts of <20/μL. A median of 07 cycles of Lenalidomide based combination therapy was used for induction therapy prior to ASCT. 84% patients underwent successful mobilization with one sitting of stem cell harvest post a single dose of Inj Plerixafor. 7.6% patients failed to mobilise the predefined minimum cell dose of CD34 and could not be taken up for ASCT. The median CD34% of the harvest bag sample was 0.33% (0.1–0.97%). Injection site erythema (34%), paresthesia’s (34%) and nausea (30%) were the commonest adverse events reported post Inj Plerixafor. We did a real-world cost analysis for a resource limited setting for PBSC mobilization and found significant cost savings for the preemptive Plerixafor group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Micallef INM, Ho AD et al (2011) Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. Bone Marrow Transplant 46:350–355

    Article  CAS  PubMed  Google Scholar 

  2. Malard F, Kreoger N et al (2012) Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biol Blood Marrow Transplant 18:309–329

    Article  Google Scholar 

  3. Popat U, Saliba R et al (2009) Impairment of filgastrim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6):718–723

    Article  PubMed  PubMed Central  Google Scholar 

  4. Sánchez-Ortega I, Querol S et al (2015) Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization. Bone Marrow Transplant 50:34–39

    Article  PubMed  Google Scholar 

  5. Giralt S, Costa L et al (2014) Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant 20:295–308

    Article  PubMed  Google Scholar 

  6. Cheng J, Schmitt M et al (2015) Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma. Transfusion 55:275–283

    Article  CAS  PubMed  Google Scholar 

  7. Mohty M, Duarte RF, Croockewit S, Hübel K, Kvalheim G, Russell N (2011) The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia 25:1–6

    Article  CAS  PubMed  Google Scholar 

  8. Jantunen E, Lemoni RM (2012) Preemptive use of plerixafor in difficult-to-mobilizepatients: an emerging concept. Transfusion 52:906–914

    Article  CAS  PubMed  Google Scholar 

  9. Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ et al (2012) Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34+ hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34+ cell count: results of a subset analysis of a randomized trial. Biol Blood Marrow Transplant 18:1564–1572

    Article  CAS  PubMed  Google Scholar 

  10. Lefrère F, Mauge L, Réa D, Ribell JA, Dal Cortivo L, Brignier AC et al (2013) A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizers: impact on the timing of the apheresis procedure. Transfusion 53:564–569

    Article  PubMed  Google Scholar 

  11. Pusic I, Jiang SY, Landua S et al (2008) Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 14:1045–1056

    Article  CAS  PubMed  Google Scholar 

  12. Alegre A, Tomas JF, Martinez-Chamorro C et al (1997) Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 20:211–217

    Article  CAS  PubMed  Google Scholar 

  13. Desikan KR, Barlogie B, Jagannath S et al (1998) Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 16:1547–1553

    Article  CAS  PubMed  Google Scholar 

  14. Bensinger W, Appelbaum F, Rowley S et al (1995) Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547–2555

    Article  CAS  PubMed  Google Scholar 

  15. Narayanasami U, Kanteti R, Morelli J et al (2001) Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 98:2059–2064

    Article  CAS  PubMed  Google Scholar 

  16. Dazzi C, Cariello A, Rosti G et al (2000) Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin’s lymphoma? Leuk Lymphoma 39:301–310

    Article  CAS  PubMed  Google Scholar 

  17. Glaspy JA (1999) Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy. Bone Marrow Transplant 23(Suppl 2):S21–S27

    Article  PubMed  Google Scholar 

  18. Kanteti R, Miller K, McCann J et al (1999) Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin’s lymphoma and Hodgkin’s disease: a clinical and molecular analysis. Bone Marrow Transplant 24:473–481

    Article  CAS  PubMed  Google Scholar 

  19. Pusic I, Jiang SY, Landua S et al (2008) Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 14:1045–1056

    Article  CAS  PubMed  Google Scholar 

  20. Alegre A, Tomas JF, Martinez-Chamorro C et al (1997) Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 20:211–217

    Article  CAS  PubMed  Google Scholar 

  21. Chao NJ, Grima DT, Carrum G et al (2011) Chemo-mobilization provides superior mobilization and collection in autologous stem cell transplants but with less predictability and at a higher cost. ASH Annual Meeting Abstracts. Blood 118:4048

    Article  Google Scholar 

  22. Desikan KR, Barlogie B, Jagannath S et al (1998) Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 16:1547–1553

    Article  CAS  PubMed  Google Scholar 

  23. Desikan KR, Tricot G, Munshi NC et al (2001) Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol 112:242–247

    Article  CAS  PubMed  Google Scholar 

  24. Dingli D, Nowakowski GS, Dispenzieri A et al (2006) Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 6:384–388

    Article  CAS  PubMed  Google Scholar 

  25. Shaughnessy Paul, Chao Nelson et al (2013) Pharmacoeconomics of hematopoietic stem cell mobilization: an overview of current evidence and gaps in the literature. Biol Blood Marrow Transplant 19:1301–1309

    Article  PubMed  Google Scholar 

  26. Gertz Morie A, Dingl David (2014) How we manage autologous stem cell transplantation for patients with multiple myeloma. Blood 124(6):882–890

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Mazumder A, Kaufman J, Niesvizky R et al (2008) Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 22:1280–1281 (author reply 1281-1282)

    Article  CAS  PubMed  Google Scholar 

  28. Micallef IN, Apostolidis J, Rohatiner AZ et al (2000) Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-hodgkin’s lymphoma. Hematol J 1:367–373

    Article  CAS  PubMed  Google Scholar 

  29. Stiff PJ (1999) Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 23(Suppl 2):S29–S33

    Article  PubMed  Google Scholar 

  30. Hosing C, Saliba RM, Ahlawat S et al (2009) Poor hematopoietic stem cell mobilizers: a single-institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 84:335–337

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Wuchter P, Ran D, Bruckner T et al (2010) Poor mobilization of hematopoietic stem cellsddefinitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 16:490–499

    Article  CAS  PubMed  Google Scholar 

  32. Haas R, Mohle R, Fruhauf S et al (1994) Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83:3787–3794

    CAS  PubMed  Google Scholar 

  33. Kumar S, Dispenzieri A, Lacy MQ et al (2007) Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21:2035–2042

    Article  CAS  PubMed  Google Scholar 

  34. Cavallo F, Bringhen S, Milone G et al (2011) Stem cell mobilization in patients with newly diagnosed multiple myeloma after Lenalidomide induction therapy. Leukemia 25:1627–1631

    Article  CAS  PubMed  Google Scholar 

  35. Tournilhac O, Cazin B, Leprètre S et al (2004) Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 103:363–365

    Article  PubMed  Google Scholar 

  36. Waterman J, Rybicki L, Bolwell B et al (2011) Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. Bone Marrow Transplant 47:488–493

    Article  PubMed  Google Scholar 

  37. Jantunen E, Kuittinen T, Nousiainen T (2003) Is chemotherapy scoring useful to predict progenitor cell mobilisation in patients with non-hodgkin’s lymphoma? Bone Marrow Transplant 32:569–573

    Article  CAS  PubMed  Google Scholar 

  38. Costa LJ, Nista EJ, Buadi FK, Lacy MQ, Dispenzieri A, Kramer CP et al (2014) Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients:implications for risk-stratification. Biol Blood Marrow Transplant 20:222–228

    Article  CAS  PubMed  Google Scholar 

  39. DiPersio JF, Micallef IN, Stiff PJ et al (2009) Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-hodgkin’s lymphoma. J Clin Oncol 27:4767–4773

    Article  CAS  PubMed  Google Scholar 

  40. Russell N, Douglas K et al (2013) Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. Hematologica 98(2):172–178

    Article  CAS  Google Scholar 

  41. Paripati H, Stewart AK, Cabou S et al (2008) Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 22:1282–1284

    Article  CAS  PubMed  Google Scholar 

  42. Basak GW, Jaksic O, Koristek Z et al (2011) Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. Am J Hematol 86:550–553

    Article  PubMed  Google Scholar 

  43. Popat R, Oakervee HE, Hallam S et al (2008) Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 141:512–516

    Article  CAS  PubMed  Google Scholar 

  44. Lu S, Wang J, Xu X et al (2009) Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience. Int J Hematol 89:34–38

    Article  CAS  PubMed  Google Scholar 

  45. Kaufman JL, Nooka A, Vrana M et al (2010) Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma. Cancer 116:3143–3151

    Article  CAS  PubMed  Google Scholar 

  46. Jakubowiak AJ, Kendall T, Al-Zoubi A et al (2009) Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 27:5015–5022

    Article  CAS  PubMed  Google Scholar 

  47. Corso A, Barbarano L, Mangiacavalli S et al (2010) Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma. Leuk Lymphoma 51:236–242

    Article  CAS  PubMed  Google Scholar 

  48. Moreau P, Hulin C, Marit G et al (2010) Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial. Leukemia 24:1233–1235

    Article  CAS  PubMed  Google Scholar 

  49. Clark RE, Bell J et al (2014) Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilization, and is effective even in heavily pretreated patients. Blood Cancer J 4(e255):1–6

    Google Scholar 

  50. Abhyankar S, Dejarnette S, Aljitawi O et al (2011) A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant 47:483–487

    Article  PubMed  Google Scholar 

  51. LaPorte J, Solomon SR, Bashey A et al (2011) An effective hematopoietic stem cell mobilization algorithm for adding plerixafor to G-CSF for multiple myeloma patients undergoing autologous transplantation. ASH Annual Meeting Abstracts. Blood 118:4389

    Google Scholar 

  52. Micallef IN, Inwards DJ, Dispenzieri A et al (2010) A risk-adapted approach utilizing plerixafor in autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 16(Suppl 2):S197–S198

    Article  Google Scholar 

  53. Costa LJ, Alexander ET, Hogan KR et al (2011) Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 46:64–69

    Article  CAS  PubMed  Google Scholar 

  54. Li J, Hamilton E, Vaughn L et al (2011) Effectiveness and cost analysis of “justin- time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 51:2175–2182

    Article  PubMed  Google Scholar 

  55. Chen AI, Bains T, Murray S et al (2012) Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization. Bone Marrow Transplant 47:1526–1529

    Article  CAS  PubMed  Google Scholar 

  56. Nademanee AP, DiPersio JF et al (2012) Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34 hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34 cell count: results of a subset analysis of a randomized trial. Biol Blood Marrow Transplant 18:1564–1572

    Article  CAS  PubMed  Google Scholar 

  57. DiPersio JF, Stadtmauer EA et al (2009) Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113:5720–5726

    CAS  PubMed  Google Scholar 

  58. Meehan KR, Areman EM, Ericson SG, Matias C, Seifeldin R, Schulman K (2000) Mobilization, collection, and processing of autologous peripheral blood stem cells: development of a clinical process with associated costs. J Hematother Stem Cell Res 9:767–771

    Article  CAS  PubMed  Google Scholar 

  59. Vishnu P, Roy V, Paulsen A, Zubair AC (2012) Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 52:55–62

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medicine and Clinical Hematology, Army Hospital (R&R), New Delhi, India

    Rajiv Kumar, Rajan Kapoor, Jasjit Singh, Tarun Verma & Ajay Sharma

  2. Pathology and Hematopathology, Army Hospital (R&R), New Delhi, India

    Bhushan Asthana

  3. Resident Medicine, Army Hospital (R&R), New Delhi, India

    Rajesh Chilaka & N. K. Singh

  4. Pediatrics and Clinical Hematology, Army Hospital (R&R), New Delhi, India

    S. Das

  5. Army Medical Services, IHQ, MOD, New Delhi, India

    Velu Nair

  6. Department of Hematology, Army Hospital (R&R), New Delhi, India

    Velu Nair

Authors
  1. Rajiv Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rajan Kapoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bhushan Asthana
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jasjit Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tarun Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rajesh Chilaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N. K. Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ajay Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Das
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Velu Nair
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Velu Nair.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kumar, R., Kapoor, R., Asthana, B. et al. Single Dose Preemptive Plerixafor for Stem Cell Mobilization for ASCT After Lenalidomide Based Therapy in Multiple Myeloma: Impact in Resource Limited Setting. Indian J Hematol Blood Transfus 33, 463–469 (2017). https://doi.org/10.1007/s12288-017-0798-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-017-0798-8

Keywords

Search

Navigation